A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)
Public ClinicalTrials.gov record NCT03192969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Combination With Glucocorticoid Treatment Compared to Glucocorticoid Monotherapy in Adults With Giant Cell Arteritis
Study identification
- NCT ID
- NCT03192969
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Abatacept Drug
- Placebo Other
- Glucocorticoid Treatment Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2017
- Primary completion
- Jun 6, 2020
- Completion
- Nov 22, 2021
- Last update posted
- Jul 11, 2017
2017 – 2021
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Phoenix | Arizona | 85032 | — |
| Local Institution | Fullerton | California | 92835 | — |
| Local Institution | West Hollywood | California | 90048 | — |
| Local Institution | Denver | Colorado | 80230 | — |
| Local Institution | Iowa City | Iowa | 52242 | — |
| Local Institution | Kansas City | Kansas | 66160 | — |
| Local Institution | Rochester | Minnesota | 55905-0001 | — |
| Local Institution | New York | New York | 10021 | — |
| Local Institution | Cleveland | Ohio | 44195 | — |
| Local Institution | Dayton | Ohio | 45417 | — |
| Local Institution | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution | Charleston | South Carolina | 29406 | — |
| Local Institution | Beaumont | Texas | 77702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03192969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03192969 live on ClinicalTrials.gov.